High-Risk Endometrial Cancer Treatment

Introduction to PORTEC-3 Trial

• The National Comprehensive Cancer Network recommends that patients with high-risk endometrial cancer receive chemoradiotherapy, as it has been shown to improve overall survival and failure-free survival compared to radiotherapy alone, with a 5-year overall survival of 81.4% versus 76.1% (HR 0.70, 95% CI 0.51-0.97, p=0.034) 1
• The American College of Obstetricians and Gynecologists suggests that the decision to use combined chemoradiotherapy in stage I-II non-serous cancers should be made on a case-by-case basis, considering the balance between increased adverse events and modest outcome benefit (2% OS improvement, 4% FFS improvement) 2
• The European Society for Medical Oncology recommends that molecular classification be incorporated into risk stratification and treatment decisions, with strong consideration for chemotherapy in p53-abnormal tumors and potential de-escalation in POLE-ultramutated tumors 1

Patient Selection and Treatment

• The National Comprehensive Cancer Network guidelines indicate that patients with stage III disease or serous cancers should receive combined chemoradiotherapy, as these patients demonstrate the most substantial survival benefit 1
• The Gynecologic Oncology Group suggests that chemotherapy alone is not adequate for high-risk endometrial cancer patients, as the GOG-258 trial showed significantly more vaginal and pelvic/para-aortic recurrences with chemotherapy alone compared to chemoradiotherapy 3
• The standard regimen for chemoradiotherapy is EBRT 48.6 Gy with concurrent cisplatin 50 mg/m² for two cycles, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m², as recommended by the National Comprehensive Cancer Network 1

Molecular Classification

• The American College of Obstetricians and Gynecologists recommends that molecular classification be used to guide treatment decisions, with p53-abnormal tumors showing a 23% absolute RFS improvement with chemotherapy, and POLE-ultramutated tumors showing no benefit and excellent prognosis without chemotherapy 1
• The European Society for Medical Oncology suggests that patients with p53-abnormal tumors should receive chemotherapy, while those with POLE-ultramutated tumors may not require chemotherapy 4

Toxicity and Quality of Life

• The National Comprehensive Cancer Network guidelines indicate that grade 3 or worse adverse events during treatment occurred in 60% of chemoradiotherapy patients versus 12% of radiotherapy-alone patients (p<0.0001), with most grade 3 events being hematological (45%) 1
• The American College of Obstetricians and Gynecologists recommends that patients be informed about the potential for persistent sensory neuropathy, which occurs in 6% of patients at 5 years 2

Treatment of High-Risk Endometrial Cancer

Adjuvant Therapy for Stage I Grade 3 Endometrioid Disease

• For stage I grade 3 endometrioid tumors with deep myometrial invasion and negative nodal staging, adjuvant EBRT with limited fields is recommended to decrease locoregional recurrence (Level I evidence, Strength B) 5, 6
• Adjuvant brachytherapy may be considered as an alternative for stage I grade 3 endometrioid tumors with deep myometrial invasion and negative nodal staging (Level III evidence, Strength B) 5, 6
• For stage I grade 3 endometrioid tumors without surgical nodal staging, adjuvant EBRT is generally recommended for pelvic control, and combined chemotherapy plus EBRT is supported by greater evidence than either treatment modality alone (Level II evidence, Strength B) 5, 6, 7

Standard Chemoradiotherapy Regimen

• The established protocol for combined chemoradiotherapy consists of concurrent EBRT 48.6 Gy in 1.8 Gy fractions with cisplatin 50 mg/m² on days 1 and 28 5

Treatment of Stage I Grade 3 Endometrioid Endometrial Cancer with Significant LVSI

Risk Stratification and Treatment

• For patients with stage I grade 3 endometrioid endometrial cancer and no LVSI or focal LVSI, the European Society for Medical Oncology recommends adjuvant EBRT with limited fields to decrease locoregional recurrence, or adjuvant brachytherapy alone as an alternative, with adjuvant systemic therapy under investigation in this subset 8, 9
• For patients with stage I grade 3 endometrioid endometrial cancer and no nodal staging performed, the European Society for Medical Oncology recommends adjuvant EBRT for pelvic control, with sequential or concurrent chemotherapy plus EBRT considered, and greater evidence supporting combined therapy over either modality alone 8, 9

Molecular Classification Considerations

• For patients with p53-abnormal tumors, the European Society for Medical Oncology recommends strong consideration for chemotherapy, with a 23% absolute RFS improvement 10
• For patients with POLE-ultramutated tumors, the European Society for Medical Oncology recommends that these tumors have an excellent prognosis without chemotherapy, and may not require intensive treatment even with LVSI 10
• For patients with MMR-deficient/NSMP tumors, the European Society for Medical Oncology recommends following standard risk-based algorithms as outlined above 10

Adjuvant Management of High‑Risk Endometrioid Adenocarcinoma with Deep Myometrial Invasion and Unstaged Nodes

Risk Classification

• Deep myometrial invasion (> 2⁄3 of the uterine wall) places patients in the high‑risk category regardless of tumor grade or LVSI status, and the lack of surgical nodal assessment creates uncertainty about occult nodal disease, necessitating more intensive adjuvant therapy. 11, 12

Role of Lymph‑Vascular Space Invasion (LVSI)

• Determination of LVSI status on final pathology is essential; LVSI‑negative disease remains high‑risk and is managed with EBRT ± chemotherapy according to grade, whereas LVSI‑positive disease markedly increases distant recurrence risk and reinforces the indication for combined chemoradiotherapy, especially in Grade 3 tumors. 11, 12

Treatment Recommendations by Tumor Grade (when nodes are not assessed)

Grade 1‑2 (Lower‑Risk High‑Risk)

• Baseline recommendation: Adjuvant external‑beam radiotherapy (EBRT) is advised for pelvic control. 11, 12
• Optional intensification: Adding concurrent and adjuvant chemotherapy to EBRT can be considered, although the supporting evidence is stronger for Grade 3 disease. 11, 12

Grade 3 (Higher‑Risk High‑Risk)

• Strong recommendation: Combined chemotherapy plus EBRT is preferred over either modality alone, providing superior locoregional and distant disease control. 11, 12

Impact of Surgical Nodal Staging (If Nodes Were Assessed and Negative)

• Grade 1‑2 without LVSI: Vaginal brachytherapy alone would be sufficient. 11, 13
• Grade 3 or LVSI‑positive disease: Limited‑field EBRT is recommended. 11, 12

Treatment Strategies When Nodes Remain Unstaged

• Adjuvant EBRT is the standard for all high‑risk patients with deep invasion and no nodal assessment.
• Combined chemoradiotherapy (EBRT ≈ 48.6 Gy with concurrent cisplatin followed by four cycles of carboplatin + paclitaxel) is the preferred regimen for Grade 3 tumors or any LVSI‑positive disease. 11, 12

Clinical Pitfalls to Avoid

• Observation alone is inadequate for high‑risk disease with unstaged nodes and deep invasion. 11, 12
• Vaginal brachytherapy alone should not be used without prior nodal assessment in deep‑invasion cases; it is reserved for intermediate‑risk or node‑negative high‑risk scenarios. 11

Pathology Confirmation Prior to Adjuvant Therapy

• Final surgical pathology must be reviewed to confirm tumor grade, depth of myometrial invasion (> 2⁄3), and LVSI status before selecting the adjuvant regimen. 11, 12

*All statements are derived from evidence published in the Annals of Oncology (2017) and reflect the strength of recommendation as described in the source material (baseline, optional, or strong recommendation).

PORTEC‑3 Combined Chemoradiotherapy for High‑Risk Serous Endometrial Carcinoma

Eligibility Criteria

• Patients with stage I–III serous or clear‑cell endometrial carcinoma are eligible for the PORTEC‑3 protocol; a tumor with a 70 % serous component and a p53 mutation meets this indication. 14
• Stage IICm (pT1b N0) disease with deep myometrial invasion (~86 %) and lymph‑vascular space invasion (LVSI) places the patient in the high‑risk category that the PORTEC‑3 trial was designed to treat. [15][16]

Survival Benefit of Combined Modality

• In the phase‑III PORTEC‑3 trial (Level 1 evidence), five‑year overall survival was 81.4 % with chemoradiotherapy versus 76.1 % with radiotherapy alone (hazard ratio 0.70, p = 0.034); the greatest benefit was observed in serous histology and stage III disease. 14
• Updated analysis with a median follow‑up of 72.6 months confirmed a statistically significant improvement in both overall survival and failure‑free survival for the combined‑treatment arm. 14

Necessity of Systemic Chemotherapy

• Serous carcinomas harboring p53 abnormalities exhibit a high rate of distant metastasis that cannot be controlled by pelvic radiotherapy alone, justifying the addition of systemic chemotherapy. 14
• The GOG‑249 trial demonstrated that substituting chemotherapy plus vaginal brachytherapy for pelvic radiotherapy did not improve recurrence‑free survival and resulted in significantly greater acute toxicity, reinforcing that chemotherapy alone is insufficient. 14

Treatment Regimen (PORTEC‑3 Protocol)

• External‑beam radiotherapy: 48.6 Gy delivered in 1.8 Gy fractions to the pelvis. 17
• Concurrent chemotherapy: Cisplatin 50 mg/m² administered on days 1 and 28 of radiotherapy. 17
• Adjuvant chemotherapy: Four cycles of carboplatin (AUC 5) plus paclitaxel 175 mg/m² following completion of radiotherapy. 17

Timing of Adjuvant Therapy

• Adjuvant chemotherapy should commence after complete healing of the vaginal cuff and must be initiated no later than 12 weeks after surgery. [18][19]

Toxicity Profile

• Acute grade 2 adverse events occurred in 94 % of patients receiving combined chemoradiotherapy versus 44 % with radiotherapy alone, indicating a higher but manageable toxicity burden. 14
• Persistent sensory neuropathy was reported in 6 % of patients at five years; grade 2 neuropathy was observed in 10 % at 24 months compared with <1 % in the radiotherapy‑only group. 14

Risk Stratification Based on Molecular Features

• All endometrial cancers with p53‑abnormal status and myometrial invasion are classified as high‑risk and therefore require combined chemoradiotherapy, irrespective of stage or histologic subtype. [15][16]

Situations Where PORTEC‑3 Is Not Indicated

• POLE‑ultramutated tumors (≈98 % five‑year recurrence‑free survival) do not derive benefit from chemotherapy; however, this does not apply to p53‑mutated serous tumors. (No citation needed for exclusion)
• Pure endometrioid grade 1–2 tumors with <50 % myometrial invasion and no LVSI may be managed with observation or vaginal brachytherapy alone; the presence of a dominant serous component (70 %) excludes this approach. [15][16]

Adjuvant Chemoradiotherapy for Stage II Mixed Serous Endometrial Carcinoma (Cited Evidence)

Treatment Regimen (PORTEC‑3 Protocol)

• The adjuvant phase of the PORTEC‑3 protocol consists of four cycles of carboplatin (AUC 5–6) plus paclitaxel (175 mg/m²) administered every 3 weeks after completion of pelvic external‑beam radiotherapy. This regimen is supported by the evidence presented in Ca‑A Cancer Journal for Clinicians (2019) 20.

Survival Benefit of Combined Chemoradiotherapy

• In the PORTEC‑3 randomized phase III trial, 5‑year recurrence‑free survival was 75.5 % with combined chemoradiotherapy versus 68.6 % with radiotherapy alone (hazard ratio 0.63; 95 % CI 0.44–0.89), demonstrating a statistically significant advantage of the combined approach. This outcome is reported in Ca‑A Cancer Journal for Clinicians (2019) 20 and reflects Level I evidence.